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ABSTRACT: Cardiovascular disease remains one of the largest
contributors to death worldwide. Improvements in cardiovascular
technology leading to the current generation of drug-eluting stents,
bioresorbable stents, and drug-eluting balloons, coupled with
advances in antirestenotic therapeutics developed by pharmaceutical
community, have had a profound impact on quality of life and
longevity. However, these procedures and devices contribute to both
short- and long-term complications. Thus, room for improvement
and development of new, alternative strategies exists. Two major
approaches have been investigated to improve outcomes following
percutaneous coronary intervention including perivascular delivery
and luminal paving. For both approaches, polymers play a major role
as controlled research vehicles, carriers for cells, and antithrombotic
coatings. With improvements in catheter delivery devices and increases in our understanding of the biology of healthy and
diseased vessels, the time is ripe for development of novel macromolecular coatings that can protect the vessel lumen following
balloon angioplasty and promote healthy vascular healing.
■ INTRODUCTION
Despite improvements in technology and healthcare fields,
coronary artery disease (CAD) remains the number one killer
of Americans, with approximately 34.3% of deaths attributed to
CAD each year.1 CAD is caused by atherosclerosis, the
accumulation of plaque on artery walls, which blocks blood flow
to the heart muscle and surrounding tissue. In an effort to
improve patient quality of life and prevent further complica-
tions like heart attack, the removal of the occlusions from the
vessel wall is critical. Percutaneous coronary intervention
(PCI), perhaps one of the most innovative medical inventions
of the century, has become an effective method for the
treatment of CAD. PCI, first developed in 1977 by Andreas
Grϋntzig and also referred to as percutaneous transluminal
coronary angioplasty, is an invasive cardiovascular procedure
performed to mechanically widen narrowed vessels in the
heart.2 Over the past 10 years, the number of PCI procedures
performed in the United States has increased by 33%, with over
1.3 million interventions implemented in 2006.1,3,4 Further, an
estimated 83.6 million American adults (>1 in 3) have one or
more types of cardiovascular disease. Of these, 42.2 million are
estimated to be ≥60 years of age.5
Although coronary revascularization was transformed by
balloon angioplasty, vessel recoil or vasospasm, resulting in the
immediate loss of luminal diameter due to vascular constriction
stemming from vessel damage inflicted during balloon inflation,
caused concern.4,6−9 The introduction of intracoronary
stenting, metal tubes, or scaffolds implanted in the vessel
during balloon angioplasty reduced elastic recoil of the vessels
by 37.5%;10 however, stenting also created new challenges
associated with the implantation of a blood-contacting
biomaterial including thrombosis, the formation of blood
clots, and neointimal hyperplasia.11 While thrombosis issues are
largely overcome by using systemic anticoagulants, neointimal
hyperplasia often prompts the need for a second procedure.12,13
This review seeks to provide context for current treatments
for PCI, detailing both a historical overview of modern
treatments, and an overview of the pathology of restenosis. In
order to approach macromolecular therapeutic design for PCI,
an understanding of the pathology of restenosis and arteries is
needed. Thus, this article starts with the pathology and then
discusses modern approaches to local delivery from balloon
catheters and stents. This is followed by an overview of the
therapeutics currently delivered from balloons and stents,
complimented with a summary detailing their mechanism of
action and limitations. Next, alternative approaches using
macromolecules are discussed and lessons learned from these
studies are highlighted. The review concludes with a short
discussion of limitations and suggests future directions for use
of macromolecules toward the development of novel
therapeutic devices to improve outcomes following PCI.
■ PATHOBIOLOGY OF RESTENOSIS
In order for researchers to prevent the damages associated with
PCI and restenosis, it is important to first understand its
pathobiology. Restenosis is characterized by a progression of
inflammation,14,15 granulation,15 smooth muscle cell (SMC)
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proliferation,16−18 and extracellular matrix (ECM) deposi-
tion18,19 (Figure 1). The occurrence of restenosis following
PCI is attributed to trauma during the procedure, triggering an
array of mechanical and biological activities implicated in the
healing process. This progression can be exacerbated by the
presence of a stent, which acts as a nucleation site for clotting
and inflammation. In uninjured vessels, the innermost layer of
vessel wall, the intima, is comprised of a monolayer of
endothelial cells (EC), which forms a tight barrier between the
lumen of the blood vessel and the rest of the vessel wall (Figure
1A). This nonthrombogenic barrier aids in the prevention of
clots, protects against inflammation, and is responsible for
signaling the underlying medial layer.20−22
Trauma during PCI strips the ECs from the vessel wall,
resulting in the elimination of important endothelium-derived
antithrombotic factors such as nitric oxide (NO) and
plasminogen activator inhibitor, among others.23,24 Further-
more, the disruption of the EC layer also exposes the
underlying medial layer, comprised of circumferentially aligned
SMCs organized throughout a matrix composed mainly of
collagen I and III (Figure 1B).25 The exposure of the collagen
matrix provides inherent targets for platelet adhesion,
activation, and aggregation,26,27 stimulating thrombus forma-
tion and the secretion of diverse pro-coagulant and mitogenic
substances.28,29 Inflammatory cells, such as neutrophils,
lymphocytes, and monocytes, are recruited to the site of injury
by surface expression of adhesion molecules, such as P-selectin,
intercellular adhesion molecule-1, and vascular cell adhesion
molecule-1, by both the injured endothelial cells and activated
platelets (Figure 1C).28,30 Furthermore, the expression of P-
selectin has been shown to accelerate the rate at which fibrin
formation and deposition occurs, which is important as fibrin
stabilizes thrombi (blood clots).31
Leukocytes, stimulated by a chemical gradient produced by
SMCs in the injured area, migrate into the tissue and release
growth factors, including platelet derived growth factor
(PDGF),32 transforming growth factor,33−35 basic fibroblast
growth factor,36 and epidermal growth factor.37−39 The release
of growth factors from these activated leukocytes, as well as
from platelets and SMCs, stimulate SMC proliferation and
migration to the neointimal layer of the vessel wall (Figure
1D).16−18 The released cytokines and growth factors also cause
the synthesis of ECM components by SMCs.40,41 The
combined migration of SMCs into the intima coupled with
ECM synthesis results in neointimal hyperplasia and reduced
blood flow.
■ LOCALIZED THERAPEUTIC DELIVERY FROM
STENT AND BALLOON PLATFORMS
To overcome the intimal hyperplasia resulting from PCI
coupled with the use of bare metal stents, drug-eluting stents
(DES) were employed to locally deliver antirestenotic
therapeutics. Since FDA approval of the first DES, it is
estimated that approximately 4.5 million DESs have been
implanted, accounting for more than 75% of all stents
deployed.42−44 To include therapeutic agents on stents, drugs
are either applied directly to the stent45−47 or impregnated
within polymer matrices.48−50 These polymeric matrices have
been designed to provide long-term release in vivo. Although
DESs have reduced restenosis rates by as much as 37.5%
compared to bare metal stents, the occurrence of late-stent
thrombosis due to delayed arterial healing, incomplete re-
endothelialization, and local inflammation, has raised concerns
about their use.10,51 The underlying reason for the development
of late-stent thrombosis from DESs remains unknown;
however, it is most likely due to the coupling of several factors,
including delayed endothelialization,52 adverse effects of the
polymer coatings,53 neointimal growth over a longer period,54
and early discontinuation of systemic antiplatelet therapy.55,56
Bioresorbable stents (BRS) were developed for use in place
of DESs, eliminating the potential consequences associated
with permanent metal implants, as BRSs provide mechanical
support to the vessel wall for a defined period of time following
PCI prior to their subsequent resorption.57 BRSs, fabricated
from either a polymer or metallic alloy, are of interest as they
provide the radial strength and low recoil characteristics
necessitated by traditional metal stents, while allowing gradual
and predictable release of impregnated therapeutics during the
Figure 1. Schematic representation of (A) a healthy vessel and (B−D) the progression of restenosis in an injured vessel following PCI (not to scale).
(A) Blood vessels have three distinct layers, intima, media, and adventitia, which are separated by elastic lamina. In a normal vessel, the intima is
comprised of a monolayer of ECs, while the media contains circumferentially aligned SMCs in a matrix of collagen. (B) After PCI, ECs are denuded
from the wall exposing the underlying collagen matrix to which platelets can bind, activate and secrete growth factors. (C) Growth factors secreted
from activated platelets recruit inflammatory cells to the site of injury and (D) stimulate SMC proliferation, migration, and ECM synthesis, ultimately
resulting in intimal hyperplasia.
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resorption of the scaffold.58,59 While BRSs protect against
vessel occlusion stemming from elastic recoil and can release
therapeutics similar to DESs, the potential for strut fracture,
leading to constrictive remodeling, and concerns regarding
fragments of the degradable stents breaking free and
subsequently occluding small vessels exist.60 In addition to
the unique consequences associated with BRS, additional
complications may arise; similar to bare metal and drug-eluting
stents, an initial mismatch in compliance between the scaffold
and the surrounding tissue exists, as well as the potential for
delayed endothelialization and the challenges associated with
the development of thrombosis remain unclear.61
An alternative to DESs and BRSs is drug-eluting balloons
(DEBs), which have recently shown promising results with
eliminating the complications caused by stents.62 However,
unlike both DESs and BRSs, the time frame for local
therapeutic delivery from DEBs is much shorter. The ability
of the balloon to transfer clinically relevant amounts of drug has
encouraged the pursuit of DEBs as effective treatment options
for the delivery of antirestenotic medication during PCI.62
Furthermore, as the prolonged exposure of the stent to blood is
eliminated, the required time for antiplatelet therapy is
shortened in DEB-only PCI procedures.63 Two of the main
strategies for local delivery from balloons have occurred via
elution of drug solution from porous balloon catheters64−66 and
drug-coated balloons.62,67,68 Porous balloons are able to directly
transfer drugs to the adjacent vessel wall using inflation
pressure, which forces the solution from the balloon lumen to
the tissue of the vessel wall; however, a delicate balance
between sufficient pressure to deliver agents into the wall of the
vessel, yet prevent mechanical wall damage must be
achieved.64,65,69,70 The use of drug-coated balloons presents
another strategy for local delivery. Therapeutics, coated onto
the surface of the balloon typically with carriers, are transferred
to the vessel wall at the time of inflation.63,68,71 In this case,
premature drug release prior to balloon inflation and during
transfer to the vessel wall, caused by rapid dissolution of
hydrophilic carriers, remains a major complication of these
drug-coated balloons.72 While both DEB strategies are
intriguing and may prove efficacious over use of stents, the
porous balloon has the additional benefit that it can deliver
hydrogel precursors, or even molecular coatings to the
damaged surface of the vessel to form soft, antithrombotic
coatings on the vessel lumen.
■ CURRENT THERAPUETIC TREATMENTS AND
LIMITATIONS
An understanding of the mode of action, as well as the
strengths and weaknesses, of antirestenotic compounds, in
addition to the limitations of stents as described above,
supports innovation around new approaches to improve upon
PCI. Advances within the pharmaceutical and scientific
communities have enabled medical researchers to develop a
wide range of antirestenotic therapeutics. As restenosis is
generally limited to the area of intervention, the investigation of
local delivery of antirestenotic compounds from both balloons
and stents has become an integral topic in modern research.
The overall goal of the developed therapies is to target the key
processes involved in the healing response leading to restenosis,
including platelet activation, inflammation, SMC proliferation
and migration, and ECM synthesis.50,73
Antirestenotic therapeutics are classified in four categories:
antiproliferative, anticoagulant, anti-inflammatory, and pro-
healing. The most popular antirestenotic therapeutics are the
antiproliferative compound, paclitaxel, and anti-inflammatory
agent, sirolimus. Table 1 lists the DESs, BRSs, and DEBs
currently utilizing these therapeutic compounds in their
formulations. Paclitaxel, which is employed as the active
ingredient in the formulations of several DESs approved for
use in the United States and Europe, as well as several BRSs
and DEBs approved for use in Europe, effectively targets and
inhibits SMC proliferation.49,74 Similarly, the anti-inflammatory
compound sirolimus, and several of its analogs, are currently
utilized as therapeutics in numerous FDA approved DESs, in
addition to several BRSs currently approved in Europe, as these
compounds have effectively limited the immunogenic response
caused by PCI and have been shown to decrease SMC
proliferation and migration in vivo.48,75−82 However, both
paclitaxel and sirolimus, like many antiproliferative and anti-
inflammatory compounds, are not cell specific and, therefore,
their effects are not limited purely to SMCs; rather, these
therapeutics exhibit a negative response on EC proliferation
and migration, ultimately hindering complete healing of the
vessel wall.80,82,83
Similar to antiproliferative and anti-inflammatory therapeu-
tics, both anticoagulant and pro-healing therapeutics have
shown success with minimizing some of the key processes
leading to restenosis; however, compounds in these two classes
are not utilized clinically on angioplasty balloons or stents due
to consequences associate with each category.1,9,76,83,84
Anticoagulant compounds, with the exception of heparin,
demonstrate poor mechanisms for re-endothelialization of the
injured vessel wall and as such, provide partially endothelialized,
fibrin-rich sites creating a stimulus for surface-induced
thrombosis.85−87 Alternatively, pro-healing biologics, which
are characterized by their ability to support re-endothelializa-
tion of the arterial wall, have been reported to minimize the
extent of SMC proliferation, platelet adhesion, and collagen
synthesis.19,88−90 Still, this class of antirestenotic therapeutics
does not attenuate every aspect of restenosis; adverse
inflammatory responses,91,92 as well as decreased vaso-
constrictive properties of injured vessels,93 have resulted after
treatment with pro-healing drugs. Therefore, as each of the four
classes of antirestenotic therapeutics demonstrates detriments
for the prevention of restenosis regardless of systemic delivery
or local delivery via stents or coated balloons, there is a need to
develop new approaches to combat thrombosis and neointimal
hyperplasia.
■ ALTERNATIVE STRATEGY FOR RESTENOTIC
TREATMENT
Two major approaches have been investigated to improve
outcomes following PCI. The first approach is to place
therapies on the adventitial side of the vessel, such that the
therapeutic will diffuse from outside of the vessel wall into the
medial and intimal layers. These perivascular remedies aim to
suppress intimal hyperplasia without potential side effects
stemming from direct contact with blood and further disruption
of the endothelium. Perivascular methods include delivery of
cells and polymeric formulations.94,95 The second approach is
to deliver therapeutics to the lumen of the blood vessel.
Approaches to the latter concept include delivery of nano-
particles and paving of the vessel lumen.96,97
Investigations aiming to improve PCI outcomes through
delivery of therapeutic treatments peripheral to the blood vessel
show promising results, but are limited by surgical access to
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implant the perivascular therapies, in addition to the PCI
procedure needed to clear the occluded vessel. Briefly, Nugent,
Rogers, and Edelman seeded ECs on Gelfoam mats, composed
of compressed gelatin, prior to surgically inserting the mats
peripheral to the vessel. Once surgically transplanted, factors
secreted by the ECs were found to influence SMC response to
vessel injury, ultimately resulting in decreased intimal hyper-
plasia following balloon angioplasty.98 In further work, Nugent
et al. demonstrated that perlecan, a proteoglycan secreted by
the seeded ECs was responsible, at least in part, for the
suppression of intimal hyperplasia.99 The findings are
encouraging because they highlight the importance of
communication between smooth muscle cells and endothelial
cells in vessel health, thus, provide further insights into
potential therapeutic strategies.
The release of small molecules and biologics from the
periphery of the vessel wall has also proven interesting. One
strategy included the delivery of polymers that produce or
release NO, a compound released by ECs to induce
vasorelaxation and minimize SMC migration, both of which
suppress intimal hyperplasia.100 Alternatively, researchers have
investigated perivascular delivery of the antiproliferative and
anti-inflammatory compounds used in drug eluting stents.101,102
Gene delivery is also a target therapy, as demonstrated by the
use of cationic polyethylenimine complexes to deliver genes
from periadventitial reservoirs.103 Finally, biodegradable poly-
mers can be used to delivery therapeutics, such as Sunitinib, an
inhibitor of both PDGF and vascular endothelial growth factor,
both of which are implicated in hyperplasia.104 The
periadvential delivery approach is sufficiently flexible to allow
delivery of a variety of therapeutics including cells, small
molecules, biologics, and combinations thereof.
Delivery of therapeutics from outside the blood vessel has
proven to be effective in animal models; however, this method
of treatment comes with advantages and disadvantages. One
main advantage of perivascular delivery is the ability to implant
therapeutics without further compromising or damaging the
lumen of the diseased vessel. There are also fewer size
limitations to the implant, as perivascular wraps are not
anticipated to directly affect blood flow by taking up key
luminal real estate or to serve as a nidus for thrombosis. Finally,
perivascular materials may employ multiple strategies for
therapeutic delivery including controlled release of NO to
suppress vasoconstriction and SMC migration, as well as the
release of antiproliferatives, and potentially even the trans-
plantation of endothelial cells. These materials are not without
complications however; a main disadvantage is that they do
require a more invasive, open surgery for implantation. While
limiting with respect to PCI, these approaches may be
particularly useful in alternative procedures where synthetic
grafts or vein grafts are deployed, and in surgical arteriovenous
fistula creation, where open surgery facilitates implantation of
the perivascular devices.
Conversely, therapeutic delivery to the lumen of the blood
vessel can be performed coincident with PCI, thus negating the
requirement for additional surgical procedures. This concept is
not new and was reviewed as early as 1994 by Slepian.105 Hill-
West et al. demonstrated in 1994 that photopolymerization of
polyethylene glycol (PEG) hydrogel barriers within the lumen
of the blood vessel both prevented platelet adhesion and also
significantly suppressed intimal hyperplasia in both a rat arterial
crush injury and a rabbit balloon angioplasty model.106 While
limited by the need to isolate the blood vessel and stop blood
flow, the work showed that thin (∼13 μm) hydrogel layers were
sufficient to suppress hyperplasia. West and Hubbell later
Table 1. Summary of Coronary DESs, BRSs, and DEBs
Impregnated with Paclitaxel or Sirolimus, and Derivatives,
Currently Approved or in Clinical Trials in the U.S. and
Europea
therapeutic device (manufacturer) type coating strut
Paclitaxel
Infinnium (SMT)b DES PLLA, PLGA,
PLC, PVP
SS
Ion (Boston
Scientific)b,c
DES SIBS PtCr
Taxus Express (Boston
Scientific)b,c
DES SIBS SS
Taxus Liberte (Boston
Scientific)b,c
DES SIBS SS
Danubio (Minvasys)b DEB butryl-tri-hexyl
citrate
Dior II (Eurocor)b DEB shellac
Elutax SV (Aachen
Resonance)b
DEB unknown
In.Pact Falcon
(Medtronic)b
DEB urea
Lutonix DCB (BARD)b DEB polysorbate/
sorbitol
Pantera Lux
(Biotronik)b
DEB butryl-tri-hexyl
citrate
Primus
(Cardionovum)b
DEB shellac
SeQuent Please (B.
Braun Melsungun)b
DEB iopromide
Sirolimus
Cypher (Cordis)b,c DES PEVA, PBM SS
Supralimus (Sahajanand
Med Tech)b
DES PLLA, PLGA,
PLC, PVP
SS
Everolimus
MiStent (Micell
Technologies)b
DES PLGA CoCr
Promus Element
(Boston Scientific)b,c
DES PVDF-HFP PtCr
SYNERGY (Boston
Scientific)b
DES PLGA PtCr
Xience V (Abbott)b,c DES PVDF-HFP CoCr
Absorb BVS (Abbott)b BRS PLLA PDLLA
Zotarolimus
Endeavor
(Medtronic)b,c
DES PC CoCr
Resolute (Medtronic)b,c DES BioLinx CoCr
Novolimus
DESyne (Elixir)b DES PLA CoCr
DESolve (Elixir)b BRS PLLA PLLA
DESolve 100 (Elixir)b BRS PLLA PLLA
Biolimus
Axxess (Biosensors
Europe)b
DES PLA Nitinol
BioMatrix (Biosensors
Europe)b
DES PLA SS
Nobori (Terumo)b DES PLA SS
aAbbreviations: CE, Conformite ́ Europeénne; CoCr, cobalt chromi-
um; PC, tyrosine-derived polycarbonate polymer; PBM, poly(n-butyl
methacrylate); PDLLA, poly(D,L-lactide); PEVA, poly(ethylene
covinyl acetate); PLA, polylactic acid; PLC, 75/25 poly-L-lactide;
PLGA, poly(lactide-co-glycolide); PLLA, poly-L-lactic acid; PtCr,
platinum chromium; PVDF-HFP, poly(vinylidene fluoride-hexafluor-
opropylene); PVP, polyvinylpyrrolidone; phosphorylcholine; SIBS,
poly(styrene-b-isobutylene-b-styrene); SS, stainless steel. bCE ap-
proved. cFDA approved.
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demonstrated that degradable photopolymerized PEG hydrogel
barriers, which degraded over a 24 h period, were equally as
effective at suppressing intimal hyperplasia as nondegradable
PEG hydrogel barriers, as determined 2 weeks following
balloon angioplasty. This result is hypothesized to be due to the
suppression of initial thrombus formation that ultimately leads
to inflammation and vessel wall thickening.107 While limited by
the need to stop blood flow and manipulate the vessel to ensure
polymerization occurs only on the luminal surface, these studies
were pivotal in showing that suppression of early interactions
between the newly denuded vessel surfaces and blood-borne
factors is critical to healthy vessel healing.
In an alternative strategy with a focus to develop vascular
paving materials that better match the vessel wall mechanical
properties, Ashton et al. developed blends of polycaprolactone
and polyurethane.108 The incorporation of polyurethane
improves compliance of the polymer, while the polycaprolac-
tone is slowly degradable and thus could be used as a controlled
release depot. While this particular construct was investigated
for abdominal aortic aneurism indications, where it may be
necessary to have a permanent component, the ability to deliver
therapeutics intraluminally may be of importance in some PCI
applications. In addition, if the surface can be made
nonthrombogenic, this kind of approach may reduce the
need for aggressive antiplatelet therapies, used to prevent
thrombosis on blood-contacting materials that come with many
complications. Similarly, Livnat, Beyer, and Seliktar developed
an interpenetrating network of PEG and alginate in the form of
a thin film.109 The film was deployed coincident with a stent to
form a barrier between the stent and the vessel wall. This
approach allowed delivery of the antithrombotic paving
material during a standard procedure without the need to
stop blood flow for a prolonged period of time. However, it
does not overcome the placement of a stent, and its associate
complications.
Returning to approaches that preclude the need to use
permanent implants, an intriguing method for coating the
luminal surface of a blood vessel is using layer-by-layer
technology. This method improves upon early hydrogel
techniques as it does not require initiator and photo-
polymerization, nor does it require insertion of a cylindrical
mold to prevent polymerization throughout the lumen of the
blood vessel. However, it does require temporary elimination of
blood from the surface to be treated, and blood flow must be
interrupted for several minutes for each layer that is deposited.
First reported by Thierry et al. layer-by-layer deposition of
polyelectrolytes was used to suppress platelet deposition on
damaged arteries and release therapeutics locally.110 Using
chitosan to first create a cationic adhesive layer on the anionic
vessel wall, alternating layers of chitosan and hyaluronic acid
were built up to form 5 bilayers. The bilayers were found to be
strongly adhesive and able to prevent platelet binding. In
addition, they were able to incorporate polyarginine, which
while reducing the incorporation of hyaluronic acid, also
decreased platelet adhesion by 30%, presumably due to
increased NO generation, over films lacking polyarginine.
Regardless of the mechanism, this study demonstrated that the
approach not only suppresses platelet binding, but can also be
adapted for incorporation of drugs to further improve
outcomes. Future studies will need to address the inability to
form these layers in the presence of blood and the length of
time needed to form each layer to adapt it to current
angioplasty techniques. Further information about this
approach can be found in reviews by Groth and Lendlein111
and by Kerdjoudj et al.112
Taking yet another tactic, Kastrup et al. developed an
adhesive hydrogel that could be painted directly onto
atherosclerotic plaques to both deliver therapeutics and to
reinforce the plaque fibrous cap.113 An alginate catechol was
synthesized that could both be cross-linked by oxidation, via
addition of periodate, and also take advantage of the
bioadhesive properties of the phenolic catechol moiety to
cross-link the alginate to the surface of the plaque. The gel was
found to withstand physiological shear stress and deliver
therapeutics. As the approach delivers therapeutics directly to
the plaque, with the aim to shrink the plaque and increase
blood flow, it precludes the need for balloon angioplasty.
Limitations of the approach include the need for about 15 min
for cross-linking; this time will need to be decreased
significantly if it is to become clinically relevant. However, it
is an exciting tactic as it may eliminate the need for PCI, and its
associated complications, in cases that are diagnosed sufficiently
early, where the immediate need to increase the lumen size, and
thus blood flow, are not needed.
Other approaches look to deliver polymer through porous
balloons, directly to the site of PCI, such that these polymers
rapidly bind to the vessel wall and form thin films. Building on
earlier work that used PEG-diisocyanate to reduce thrombus
formation on Dacron vascular grafts, Deglau et al. delivered N-
hydroxysuccinimide-PEG (NHS-PEG) to the arterial surface
using the Boston Scientific Remedy balloon.114 NHS forms
covalent cross-links with primary amines, thus, allowing the
polymer to graft to both endothelial cells and denuded vascular
surfaces. In a rabbit femoral angioplasty model, 67% of the
grafted polymer remained covalently bound 72 h postdelivery
compared to the amount of polymer grafted at time zero. The
loss of polymer coating is attributed to protein turnover at the
injury site.115 While no data is presented on long-term
suppression of intimal hyperplasia, there will likely be a positive
impact based on early suppression of platelet binding.
Interestingly, the grafted polymer also contained biotin. As
avidin binds strongly to biotin (Ka = 10
15 L/mol), the biotin
was used to subsequently deliver avidin-conjugated micro-
particles, via intravenous injection, to the luminal vascular
coating. While the vast majority of the microparticles were
washed away after 72 h, nanoparticles with a higher surface area
may prove more stable. Importantly, this study shows that the
luminal coatings can be adapted to not only inhibit early
platelet binding and activation, as well as the subsequent
biological events that lead to intimal hyperplasia, but also they
can be used to target therapeutics to the site of injury.115
Aiming to mimic the antithrombotic properties of the native
glycocalyx, a 2011 study by Paderi et al. demonstrated that the
glycosaminoglycan dermatan sulfate could be conjugated to
collagen-binding peptides and subsequently delivered through a
porous angioplasty balloon at the site of angioplasty to rapidly
coat the luminal surface of denuded blood vessels.116 Dermatan
sulfate, a glycosaminoglycan (GAG) native to arteries,
mimicked the anionic nature of the GAG-rich glycocalyx on
the endothelial cell surface, while the collagen binding peptides
supported rapid and prolonged binding of the GAG only to
collagen exposed following balloon injury. The material, DS-
SILY, was delivered over 15−30 s using a porous delivery
balloon, which served to slow blood flow and deliver the
compound to the intervention site; flow was restored
immediately following delivery. Results suggested reduced
Biomacromolecules Review
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platelet binding to coated surfaces in vitro, as well as inhibited
vasospasm or elastic recoil, following PCI. In addition, this
work showed that DS-SILY did not bind to the healthy
endothelium and is thus unlikely to affect function of these
intact cells. In follow-on studies in the Ossabaw pig model,
Scott et al. further demonstrated that delivery of DS-SILY
inhibited both early platelet binding to the blood vessel at the
angioplasty site, as well as intimal hyperplasia 28 days
postangioplasty, in the presence or absence of bare metal
stents.117 These studies demonstrate that as we begin to
understand the biological triggers to disease states, tissue
healing, and regeneration, we can combine that knowledge with
our understanding of polymer chemistry as a means of
developing new polymers that are able interact intimately
with tissues to improve healing and regeneration.
■ CONCLUSIONS AND FUTURE PERSPECTIVES
Since the revolutionary development of balloon angioplasty, we
have gained a significant understanding of the biological
triggers that lead to vasoconstriction, thrombosis, restenosis,
and ultimately reduced blood flow following balloon
angioplasty. While stents were developed to resist elastic recoil,
vascular paving studies have shown that recoil can be
eliminated, or at least significantly reduced simply by
eliminating platelet contact from the lumen surface for about
24 h following PCI. This calls into question the need for
deployment of metal stents in cases where PCI does not result
in dissection of the vessel and allows development of
biomimetic polymers that can be used to temporarily repave
the vascular surface to protect the vessel from platelet binding
and the subsequent recruitment of neutrophils and monocytes.
Table 2 shows the ideal characteristics of paving materials. The
ability to synthesize multifunctional polymers also provides the
opportunity to incorporate drug delivery into these polymer
coatings. As shown by Deglau et al.115 researchers can think
beyond delivery of therapeutics at the time of PCI, but can also
engineer particle capture systems into the paving material to
recharge the therapeutic for longer-term delivery. By capital-
izing on our ever-increasing understanding of the biology of the
vascular system, biomacromolecules can be developed that
work with the biology to induce healthy healing without the
long-term consequences of implantation of foreign materials.
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